Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

(2022) Katherine Pisters et al.   JOURNAL OF CLINICAL ONCOLOGY

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

(2022) L. Paz-Ares et al.   ANNALS OF ONCOLOGY

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy

(2021) J. Remon et al.   ANNALS OF ONCOLOGY

FDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review

(2021) Abigail L. Koch et al.   CLINICAL CANCER RESEARCH

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

(2021) Enriqueta Felip et al.   LANCET

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

(2021) Jianxing He et al.   Lancet Respiratory Medicine

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)

(2021) Hirohito Tada et al.   JOURNAL OF CLINICAL ONCOLOGY

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

(2021) Yi-Long Wu et al.   Journal of Thoracic Oncology

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

(2018) Yi-Long Wu et al.   Clinical Lung Cancer

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

(2018) Wen-Zhao Zhong et al.   LANCET ONCOLOGY

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

(2018) Yi-Long Wu et al.   JOURNAL OF CLINICAL ONCOLOGY

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

(2018) Song-Tao Xu et al.   Journal of Thoracic Oncology

Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is ‘cured’ from postoperative recurrence?

(2017) Keigo Sekihara et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

(2017) Mark G. Kris et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer

(2016) Solange Peters et al.   CANCER TREATMENT REVIEWS

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

(2015) Karen Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

(2014) Solange Peters et al.   Journal of Thoracic Oncology

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY